US Pharma MarketingAstraZeneca eyes Keytruda
At ESMO, AstraZeneca pitches Imfinzi-Padcev in bladder cancer, Lilly touts FRα ADC Sofe-M and Bayer’s Nubeqa cuts metastasis risk 58%. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
MADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli Lilly and Bayer.
...
Source: Endpoints News